Standard anti-tuberculosis treatment and hepatotoxicity: do dosing schedules matter? Source: Eur Respir J 2007; 29: 347-351 Year: 2007
Incidence and timing of hepatotoxicity due to anti-tuberculous treatment Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002
Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children Source: Eur Respir J, 57 (1) 2001756; 10.1183/13993003.01756-2020 Year: 2021
Safety and acceptability of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Efficiency of treatment regimens for chronic tuberculosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003
Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis Source: Eur Respir J 2006; 28: Suppl. 50, 128s Year: 2006
The efficacy, safety and tolerability of the short 12-month pre-XDR-TB regimen regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017
The effects of bedaquiline and fluoroquinolone-based treatment regimens in patients with MDR/XDR-TB on QT prolongation Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
The efficacy, safety and tolerability of the short 12-month MDR-TB regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now? Year: 2017
Use of shortened chemotherapy regimens in treatment of adolescents with MDR/XDR TB Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018
Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004
Side-effect in the treatment of pulmonary tuberculosis by first-line drugs Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009
Impact of drug resistance over sputum conversion in tubercular patients receiving re-treatment regimen Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011
Efficacy of a standard chemotherapy regimen in the management of sputum-positive pulmonary TB relapses Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003
Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006